ClinicalTrials.gg
RecruitingNCT07659847Updated Jun 22, 2026

Cardiovascular Assessment 5 Years After MIS-C

An observational study in Multisystem Inflammatory Syndrome in Children (MIS-C) and SARS-CoV-2 Infection, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Medical University of Warsaw · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Sex
All
01

Study summary

Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system. Although acute cardiac abnormalities usually resolve, the long-term cardiovascular consequences of MIS-C remain uncertain. Previous follow-up of this cohort 2 years after MIS-C identified signs of subclinical cardiovascular abnormalities compared with healthy controls.

This cross-sectional study aims to evaluate cardiovascular health in individuals 5 years after MIS-C. Participants with a history of MIS-C will be compared with age- and sex-matched healthy controls using cardiovascular imaging, vascular assessments, cardiopulmonary exercise testing, and biomarkers of endothelial injury.

Read the detailed description

Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe hyperinflammatory condition associated with SARS-CoV-2 infection. Cardiovascular involvement is common during the acute phase of the disease and may include myocardial dysfunction, arrhythmias, hypotension, and coronary artery abnormalities. Although most patients experience rapid clinical recovery following immunomodulatory treatment, the long-term cardiovascular consequences of MIS-C remain incompletely understood.

The investigators previously evaluated cardiovascular health approximately 2 years after MIS-C and found evidence of subclinical cardiovascular abnormalities, including higher blood pressure values, increased concentrations of biomarkers associated with endothelial injury, and increased carotid intima-media thickness compared with healthy controls. These findings suggested that vascular changes may persist beyond the acute phase of the disease.

The aim of the present study is to assess cardiovascular health 5 years after MIS-C and to determine whether cardiovascular abnormalities remain detectable in long-term follow-up.

This is a cross-sectional study with a healthy control group. The MIS-C group will consist of individuals who were hospitalized with MIS-C at the Department of Pediatrics of the Medical University of Warsaw Children's Clinical Hospital between October 2020 and February 2021. Healthy controls will be recruited from primary care clinics and matched to the MIS-C group by age and sex.

All participants will undergo a comprehensive cardiovascular evaluation including:

  • laboratory testing (complete blood count, fasting glucose, HbA1c, lipid profile);
  • assessment of endothelial injury biomarkers, including galectin-3, soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble intercellular adhesion molecule-1 (sICAM-1);
  • arterial stiffness assessment using pulse wave analysis and pulse wave velocity measurements;
  • carotid intima-media thickness (cIMT) ultrasound;
  • transthoracic echocardiography;
  • cardiopulmonary exercise testing on a cycle ergometer.

The primary outcome is aortic (central) systolic blood pressure. Secondary outcomes include peripheral blood pressure, vascular stiffness parameters, carotid intima-media thickness, echocardiographic parameters, cardiopulmonary exercise test results, and concentrations of galectin-3, sICAM-1, and sVCAM-1. Outcomes will be compared between participants with a history of MIS-C and healthy controls to determine whether subclinical cardiovascular abnormalities persist 5 years after MIS-C.

The study is expected to provide important information regarding the long-term cardiovascular health of post-MIS-C patients and may help identify individuals who could benefit from ongoing cardiovascular surveillance.

02

Conditions studied

  • Multisystem Inflammatory Syndrome in Children (MIS-C)
  • SARS-CoV-2 Infection

Keywords

  • Pediatric Inflammatory Multisystem Syndrome (PIMS)
  • SARS-CoV-2
  • Endothelial Dysfunction
  • Cardiovascular Health
  • Long-Term Outcomes
  • Multisystem Inflammatory Syndrome in Children (MIS-C)
  • Arterial Stiffness
03

In context

pediatric multisystem inflammatory disease, COVID-19 related

29 studies on the registry are indexed under pediatric multisystem inflammatory disease, COVID-19 related; 8 are open to participants now.

This study's planned enrollment of 90 is below the median of 212 across 22 observational studies indexed under pediatric multisystem inflammatory disease, COVID-19 related.

Browse pediatric multisystem inflammatory disease, COVID-19 related studies →

Lead sponsor

Medical University of Warsaw is the lead sponsor of 327 studies on the registry; 88 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study Population

MIS-C group: Individuals hospitalized at the Children's Clinical Hospital of the Medical University of Warsaw with a diagnosis of multisystem inflammatory syndrome in children (MIS-C) between October 2020 and February 2021.

Control group: Healthy age- and sex-matched individuals recruited from primary care clinics in Warsaw.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For the MIS-C group: History of MIS-C diagnosed according to World Health Organization (WHO) criteria
  • For all participants: Written from a parent or legal guardian and, where applicable, assent/consent from participants aged 16 years or older /

Exclusion criteria

Exclusion Criteria:

MIS-C group:

  1. Known heart disease, including congenital heart disease.
  2. Significant chronic disease affecting growth, development, or daily functioning.

Control group:

  1. Elimination diet.
  2. Competitive athletic training.
  3. Known heart disease, including congenital heart disease.
  4. Significant chronic disease affecting growth, development, or daily functioning.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • MIS-C group

    Children and young adults 5 years after MIS-C

  • Healthy controls

    Children and young adults without significant chronic disease, frequency-matched to the MIS-C group by age, sex, and BMI.

06

What researchers measure

Primary outcomes

  1. Aortic (central) systolic blood pressure

    Central systolic blood pressure measured using pulse wave analysis.

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

Secondary outcomes

  1. Peripheral blood pressure

    Peripheral systolic and diastolic blood pressure measurements

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

  2. Arterial stiffness

    Vascular stiffness assessed by pulse wave velocity and pulse wave analysis-derived parameters

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

  3. Carotid intima-media thickness

    Carotid intima-media thickness measured by ultrasound

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

  4. Endothelial injury biomarker concentrations

    Serum concentrations of galectin-3, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1)

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

  5. Echocardiographic parameters

    Cardiac structure and function assessed by transthoracic echocardiography

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

  6. Cardiopulmonary exercise capacity

    Exercise capacity and cardiopulmonary response assessed by cardiopulmonary exercise testing on a cycle ergometer.

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

  7. Comparison of cardiovascular outcomes between MIS-C participants and healthy controls

    Comparison of cardiovascular, vascular, and endothelial function parameters between participants with a history of MIS-C and healthy controls.

    Time frame: At the study visit, approximately 5 years after MIS-C diagnosis

07

Study locations

1 of 1 sites recruiting
  • Medical University of Warsaw Children's Clinical Hospital
    Warsaw, Masovian Voivodeship, Poland
    Recruiting
08

References and documents

Publications

  • Belhadjer Z, Meot M, Bajolle F, Khraiche D, Legendre A, Abakka S, Auriau J, Grimaud M, Oualha M, Beghetti M, Wacker J, Ovaert C, Hascoet S, Selegny M, Malekzadeh-Milani S, Maltret A, Bosser G, Giroux N, Bonnemains L, Bordet J, Di Filippo S, Mauran P, Falcon-Eicher S, Thambo JB, Lefort B, Moceri P, Houyel L, Renolleau S, Bonnet D. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation. 2020 Aug 4;142(5):429-436. doi: 10.1161/CIRCULATIONAHA.120.048360. Epub 2020 May 17. PubMed 32418446 ↗
  • Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP, Leung JW, Tsang CA, Pierce TJ, Kennedy JL, Hammett TA, Belay ED. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021 May;5(5):323-331. doi: 10.1016/S2352-4642(21)00050-X. Epub 2021 Mar 10. PubMed 33711293 ↗
  • Clark BC, Sanchez-de-Toledo J, Bautista-Rodriguez C, Choueiter N, Lara D, Kang H, Mohsin S, Fraisse A, Cesar S, Sattar Shaikh A, Escobar-Diaz MC, Hsu DT, Randanne PC, Aslam N, Kleinmahon J, Lamour JM, Johnson JN, Sarquella-Brugada G, Chowdhury D. Cardiac Abnormalities Seen in Pediatric Patients During the SARS-CoV2 Pandemic: An International Experience. J Am Heart Assoc. 2020 Nov 3;9(21):e018007. doi: 10.1161/JAHA.120.018007. Epub 2020 Sep 22. PubMed 32957826 ↗
  • Krupickova S, Bautista-Rodriguez C, Hatipoglu S, Kang H, Fraisse A, Di Salvo G, Piccinelli E, Rowlinson G, Lane M, Altamar Bermejo I, Moscatelli S, Wage R, Mohiaddin R, Pennell DJ, Voges I. Myocardial deformation assessed by CMR in children after multisystem inflammatory syndrome (MIS-C). Int J Cardiol. 2022 Jan 1;346:105-106. doi: 10.1016/j.ijcard.2021.11.036. Epub 2021 Nov 16. PubMed 34798209 ↗
  • Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS Jr, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG; Overcoming COVID-19 Investigators. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 Mar 16;325(11):1074-1087. doi: 10.1001/jama.2021.2091. PubMed 33625505 ↗
  • Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse A, Miller O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A, Shimizu C, Herberg J, Burns JC, Lyall H, Levin M; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020 Jul 21;324(3):259-269. doi: 10.1001/jama.2020.10369. PubMed 32511692 ↗
  • Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, Avis J, Lynn RM, Davis P, Bharucha T, Pain CE, Jyothish D, Whittaker E, Dwarakanathan B, Wood R, Williams C, Swann O, Semple MG, Ramsay ME, Jones CE, Ramanan AV, Gent N, Ladhani SN. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national surveillance, United Kingdom and Ireland, 2020. Lancet Reg Health Eur. 2021 Apr;3:100075. doi: 10.1016/j.lanepe.2021.100075. Epub 2021 Mar 22. PubMed 34027512 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartActual
Nov 22, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07659847
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Nov 22, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Weronika Woźniak-Szewczyk, MD
Contact
wwozniakszewczyk@gmail.com
+48 22 317 9231
Magdalena Okarska-Napierała, MD PhD
Contact
magdalena.okarska-napierala@wum.edu.pl
+48 22 317 9231

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion